Farhana Chowdhury, MD
Nephrology · Newark, DENPI 1710218235
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations.
Across 159 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$569
- Fresenius USA Marketing, Inc.$388
- AstraZeneca$265
- Mallinckrodt Hospital Products Inc.$245
- Vifor Pharma, Inc.$238
- Otsuka America Pharmaceutical, Inc.$176
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,26798%
- Education$792%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 25 | $569 |
| Fresenius USA Marketing, Inc. | 16 | $388 |
| AstraZeneca(2 entities) | 12 | $265 |
| Mallinckrodt Hospital Products Inc. | 9 | $245 |
| Vifor Pharma, Inc. | 13 | $238 |
| Otsuka America Pharmaceutical, Inc. | 10 | $176 |
| Bayer | 9 | $167 |
| Novartis | 4 | $157 |
| Boehringer Ingelheim | 8 | $134 |
| Daiichi Sankyo Inc. | 7 | $114 |
| Nxstage Medical, Inc. | 2 | $104 |
| Ardelyx, Inc. | 5 | $94 |
| GSK | 6 | $93 |
| OPKO Pharmaceuticals, LLC | 6 | $87 |
| Calliditas Therapeutics US Inc. | 5 | $85 |
| Travere Therapeutics, Inc. | 5 | $83 |
| Aurinia Pharma U.S., Inc. | 3 | $66 |
| Akebia Therapeutics Inc | 3 | $54 |
| Sanofi | 2 | $52 |
| Kyowa Kirin, Inc. | 2 | $34 |
| AMAG Pharmaceuticals, Inc. | 2 | $28 |
| Scpharmaceuticals Inc. | 1 | $28 |
| Gilead | 1 | $27 |
| Novo Nordisk | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
How this compares
$3,345 in reported general payments places this provider in the 65th percentile of 49 nephrology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 21 | $23,742 |
| JardianceEmpagliflozin | 26 | $16,300 |
| DiovanValsartan | 12 | $4,455 |
| Calcitriol | 100 | $2,479 |
| Losartan Potassium | 147 | $1,648 |
| Amlodipine Besylate | 109 | $1,087 |
| Furosemide | 181 | $806 |
| Bumetanide | 14 | $706 |
| Potassium Chloride | 28 | $416 |
| Metoprolol Succinate | 17 | $338 |
| Hydralazine Hcl | 20 | $280 |
| Lisinopril | 44 | $266 |
| Chlorthalidone | 23 | $255 |
| Clonidine Hcl | 21 | $215 |
| Carvedilol | 25 | $173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $265 | $23,74221 claims |
| Boehringer IngelheimJardiance | $134 | $16,30026 claims |
| NovartisDiovan | $157 | $4,45512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 49 nephrology providers in Delaware.
Other nephrology in Newark
- Prayus TailorNewark$127K
- William DahmsNewark$94K
- Theodore SaadNewark$26K
- Nealanjon DasNewark$6K
- Manthodi FaisalNewark$6K
- Piyaporn ApivatanagulNewark$5K
- Lindsey SlaterNewark$4K
- Christopher CanfieldNewark$3K
- Feroz Abubacker KaniyamparambilNewark$3K
- Carlos MachadoNewark$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.